Dosimetric parameters of the new design 103Pd brachytherapy source based on Monte Carlo study

被引:14
作者
Saidi, Pooneh [2 ]
Sadeghi, Mahdi [1 ]
Shirazi, Alireza [3 ]
Tenreiro, Claudio [4 ]
机构
[1] Nucl Sci & Technol Res Inst, Agr Med & Ind Res Sch, Gohardasht 1439951113, Kkaraj, Iran
[2] Islamic Azad Univ, Sci & Res Branch, Dept Nucl Engn, Tehran 1477893855, Iran
[3] Univ Tehran Med Sci, Dept Biophys, Fac Med, Tehran 1417863181, Iran
[4] SungKyunKwan Univ, Dept Energy Sci, Suwon 440746, South Korea
来源
PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS | 2012年 / 28卷 / 01期
关键词
Monte Carlo calculation; Brachytherapy; TG-43U1; MCNP5; (103)pd; I-125; SEEDS;
D O I
10.1016/j.ejmp.2010.12.005
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In this study version 5 of the MCNP photon transport simulation was used to calculate the dosimetric parameters for new palladium brachytherapy source design following AAPM Task Group No. 43U1 report. The internal source components include four resin beads of 0.6 mm diameters with Pd-103 uniformly absorbed inside and one cylindrical copper marker with 1.5 mm length. The resin beads and marker are then encapsulated within 0.8 mm in diameter and 4.5 mm long cylindrical capsule of titanium. The dose rate constant, Lambda, line and pointsource radial dose function, g(L)(r) and g(p)(r), and the anisotropy function, F(r,theta) of the IR01-Pd-103 seed have been calculated at distances from 0.25 to 5 cm. All the results are in good agreement with previously published thermoluminescence-dosimeter measured values [3] for the source. The dosimetric parameters calculated in this work showed that in dosimetry point of view, the IR01-Pd-103 seed is suitable for use in brachytherapy of prostate cancer. (C) 2010 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:13 / 18
页数:6
相关论文
共 18 条
  • [1] Cross section Evaluation Working Group, 2000, BNLNCS17541 NAT NUCL
  • [2] Dosimetric characteristics of a new 125I brachytherapy source
    Gearheart, DM
    Drogin, A
    Sowards, K
    Meigooni, AS
    Ibbott, GS
    [J]. MEDICAL PHYSICS, 2000, 27 (10) : 2278 - 2285
  • [3] King R P, 2001, J Appl Clin Med Phys, V2, P69, DOI 10.1120/1.1349413
  • [4] Monte Carlo calculations and experimental measurements of dosimetry parameters of a new 103Pd source
    Li, ZF
    Palta, JR
    Fan, JJ
    [J]. MEDICAL PHYSICS, 2000, 27 (05) : 1108 - 1112
  • [5] Dosimetric characteristics of the Best® double-wall 103Pd brachytherapy source
    Meigooni, AS
    Bharucha, Z
    Yoe-Sein, M
    Sowards, K
    [J]. MEDICAL PHYSICS, 2001, 28 (12) : 2568 - 2575
  • [6] COMS eye plaque brachytherapy dosimetry simulations for 103Pd, 125I, and 131Cs
    Melhus, Christopher S.
    Rivard, Mark J.
    [J]. MEDICAL PHYSICS, 2008, 35 (07) : 3364 - 3371
  • [7] *MONT CARL TEAM, MCNP A GEN MONT CARL
  • [8] Measurement of dose-rate constant for 103Pd seeds with air kerma strength calibration based upon a primary national standard
    Nath, R
    Yue, N
    Shahnazi, K
    Bongiorni, PJ
    [J]. MEDICAL PHYSICS, 2000, 27 (04) : 655 - 658
  • [9] 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer
    Potters, L
    Morgenstern, C
    Calugaru, E
    Fearn, P
    Jassal, A
    Presser, J
    Mullen, E
    [J]. JOURNAL OF UROLOGY, 2005, 173 (05) : 1562 - 1566
  • [10] Monte Carlo and experimental characterization of the first AMIRS 103Pd brachytherapy source
    Raisali, Gholamreza
    Ghonchehnazi, Maryam G.
    Shokrani, Parvaneh
    Sadeghi, Mahdi
    [J]. APPLIED RADIATION AND ISOTOPES, 2008, 66 (12) : 1856 - 1860